<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00737061</url>
  </required_header>
  <id_info>
    <org_study_id>P0071</org_study_id>
    <nct_id>NCT00737061</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy Study of the Adiana System for Women Who Desire Permanent Birth Control (Sterilization)</brief_title>
  <acronym>EASE</acronym>
  <official_title>A Multi-Center, Prospective Evaluation of the Adiana System for Transcervical Sterilization Using Electrothermal Energy in Women Aged 18-45 - The EASE Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hologic, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>QST Consultations, Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hologic, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the safety &amp; efficacy of the Adiana Transcervical
      Sterilization System for women who desire permanent birth control (female sterilization) by
      occlusion of the fallopian tubes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants who demonstrated to be bilaterally occluded by hysterosalpingogram (HSG)
      evaluations are allowed to rely on the Adiana System for pregnancy prevention and enter the
      Wearing Period of follow-up.

      Secondary endpoints inlcude safety of device placement procedure and safety of device
      wearing. The adverse events recorded during the course of the study are entered under adverse
      events.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Product Pre-Market Approval withdrawn
  </why_stopped>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">February 4, 2013</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1 Year Pregnancy Rate</measure>
    <time_frame>1 year</time_frame>
    <description>Pregnancy rate is defined as the cumulative percentage of pregnancies occuring within the time frame. The primary endpoint for this study is the pregnancy prevention rate after one year of reliance on the Adiana System for pregnancy prevention. The pregnancy rate was evaluated for all participants who underwent successful bilateral treatment and who had demonstrated tubal occlusion by hysterosalpingogram (HSG) at the end of the Waiting Period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device Placement Rate</measure>
    <time_frame>After First Treatment Attempt</time_frame>
    <description>Defined as successful bilateral tubal access followed by successful bilateral RF treatment and matrix placement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Placement Rate</measure>
    <time_frame>Including Second Treatment Attempt</time_frame>
    <description>Defined as successful bilateral tubal access followed by successful bilateral RF treatment and matrix placement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Placement Procedure</measure>
    <time_frame>48 hours</time_frame>
    <description>Determined by verbal questions up to 48 hours post placement. Endpoint reported represents minimum percentage of participants reporting somewhat satisfied, satisfied or very satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Device Wearing</measure>
    <time_frame>Waiting Period (1-Month, 2-Months, 3-Months)</time_frame>
    <description>Determined by verbal questions during periodic follow-up contacts. Endpoint reported represents minimum percentage of subjects reporting somewhat satisfied, satisfied or very satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Device Wearing</measure>
    <time_frame>Wearing Period (3-Months, 6-Months, 9-Months, 12-Months)</time_frame>
    <description>Determined by verbal questions during periodic follow-up contacts. Endpoint reported represents minimum percentage of subjects reporting somewhat satisfied, satisfied or very satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Comfort With Placement Procedure</measure>
    <time_frame>Post-Procedure</time_frame>
    <description>Determined by verbal questions two hours following procedure or at discharge from facility, whichever came first. Endpoint reported represents minimum percentage of participants reporting any discomfort or pain experienced during the procedure as the same as or less than they expected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Comfort With Placement Procedure</measure>
    <time_frame>48 hours</time_frame>
    <description>Determined by verbal questions up to 48 hours post placement. Endpoint reported represents minimum percentage of participants reporting any discomfort or pain experienced in first 48 hours following procedure as the same as they expected, less than they expected or no pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Comfort With Device Wearing</measure>
    <time_frame>Waiting Period (1-Month, 2-Months, 3-Months)</time_frame>
    <description>Determined by verbal questions during periodic follow-up contacts. Endpoint represents minimum percentage of subjects reporting good, very good or excellent comfort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Comfort With Device Wearing</measure>
    <time_frame>Wearing Period (3-Months, 6-Months, 9-Months, 12-Months)</time_frame>
    <description>Determined by verbal questions during periodic follow-up contacts. Endpoint represents minimum percentage of subjects reporting good, very good or excellent comfort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 Year Pregnancy Rate</measure>
    <time_frame>3 years</time_frame>
    <description>Pregnancy rate is defined as the cumulative percentage of pregnancies occuring within the time frame. The pregnancy rate was evaluated for all participants who underwent successful bilateral treatment and who had demonstrated tubal occlusion by hysterosalpingogram (HSG) at the end of the Waiting Period who have been followed for up to 3 years.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">770</enrollment>
  <condition>Reproductive Sterilization</condition>
  <arm_group>
    <arm_group_label>Adiana Transcervical Sterilization System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Adiana Transcervical Sterilization System</intervention_name>
    <description>Implantation of silicone matrix in fallopian tubes</description>
    <arm_group_label>Adiana Transcervical Sterilization System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â€¢ Women aged 18 to 45

               -  Women who are seeking permanent contraception

               -  Women who are at risk of becoming pregnant

               -  Willing to risk becoming pregnant when relying on the Adiana device for
                  contraception

               -  Relatively normal uterine cavity, uterine wall thickness, and uterine size as
                  demonstrated by pelvic sonography

               -  Willing to keep a coital/menstrual log

               -  Have at least one confirmed pregnancy and one living child

               -  Monogamous relationship with a partner who has proven fertility

               -  Sexually active (at least 4 acts of intercourse per month)

               -  Willing to use alternate contraception (either a barrier method or oral
                  contraceptive pills or other monthly, cyclic, hormonal birth control) during the
                  three months following device placement prior to relying on the Adiana device for
                  contraception

               -  Willing and able to maintain in regular contact with the investigator

               -  Women with regular, cyclical menses within 2 months prior to the device placement
                  procedure

               -  Able to provide informed consent

        Exclusion Criteria:

          -  Women who are unsure of their desire to end their fertility

          -  Presence of gross genital infection, including sepsis

          -  Presence of chlamydia, gonorrhea or syphilis

          -  Presence of genital cancer (note: CIN1 is acceptable)

          -  Intra-uterine pathology which would prevent optimal access to the tubal ostium and
             intramural portion of the fallopian tube, such as large submucous fibroids or uterine
             adhesions

          -  History of chronic pelvic pain (present within the previous year), prior ectopic
             pregnancy, or fallopian tube surgery, or currently diagnosed severe dysmenorrhea,
             severe dyspareunia, endometriosis, adenomyosis, or pelvic inflammatory disease

          -  Women with unresolved tubal, ovarian or endometrial pathology

          -  Uterine neoplasia or precursors to neoplasia

          -  Dysfunctional uterine bleeding or intermenstrual bleeding within the prior three
             months

          -  Women who have not had at least two normal periods after the following events:
             irregular periods treated with oral contraceptives (or other monthly, cyclic, hormonal
             birth control) which have since been discontinued, IUD removal, childbirth, or
             termination of pregnancy

          -  Currently taking immunosuppressive medications including steroids

          -  Pregnancy

          -  Uterine perforation within the last 3 months

          -  Contraindications for surgical methods of sterilization

          -  Less than three months have passed since the last delivery or abortion
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Evantash, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hologic, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Women's Health Research</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>San Rafael</city>
        <state>California</state>
        <zip>94903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reproductive Science Center</name>
      <address>
        <city>San Ramon</city>
        <state>California</state>
        <zip>94583</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Fertility and Women's Health</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Women's Health and Body</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Reproductive Medicine</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newton-Wellesley Hospital</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Gynecology and Surgery</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Fertility Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reproductive Specialty Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Women</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario UANL</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2008</study_first_submitted>
  <study_first_submitted_qc>August 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2008</study_first_posted>
  <results_first_submitted>August 26, 2009</results_first_submitted>
  <results_first_submitted_qc>December 14, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 25, 2013</results_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Female</keyword>
  <keyword>Sterilization</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled in the trial from 16 investigative sites between November 13, 2002 and April 28, 2005. Fourteen sites were located in the US and two were international sites.</recruitment_details>
      <pre_assignment_details>770 subjects were enrolled: 75 withdrew consent and 50 were excluded for pathology/procedural criteria. All subjects were enrolled on an intent to treat (ITT) basis. The ITT population included all patients who were enrolled in the study and had device placement attempted. 645 subjects had treatment attempted. No comparative assessment was made.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Adiana Permanent Contraception System</title>
          <description>Implantation of silicone matrix in fallopian tubes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Waiting Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="645"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="570"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Bilateral placement failure</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Deemed patent following HSG</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Alternative contraception failure</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Elected surgical tubal ligation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>1 Year Wearing Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="570"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="553"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinued reilance</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Terminated for protocol non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adiana Permanent Contraception System</title>
          <description>Implantation of silicone matrix in fallopian tubes</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="645"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="645"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>All Participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.5" lower_limit="20" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="645"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>1 Year Pregnancy Rate</title>
        <description>Pregnancy rate is defined as the cumulative percentage of pregnancies occuring within the time frame. The primary endpoint for this study is the pregnancy prevention rate after one year of reliance on the Adiana System for pregnancy prevention. The pregnancy rate was evaluated for all participants who underwent successful bilateral treatment and who had demonstrated tubal occlusion by hysterosalpingogram (HSG) at the end of the Waiting Period.</description>
        <time_frame>1 year</time_frame>
        <population>645 participants had treatment attempted; Intent to Treat population. Of these 645, 570 were able to rely on the device and are used to evaluate the pregnancy prevention rate for the 1-year endpoint. During the 1-year follow-up period, there were 6 pregnancies, of which 3 were attributable to physician error, i.e., misinterpretation of HSG results.</population>
        <group_list>
          <group group_id="O1">
            <title>Adiana Permanent Contraception System</title>
            <description>Implantation of silicone matrix in fallopian tubes</description>
          </group>
        </group_list>
        <measure>
          <title>1 Year Pregnancy Rate</title>
          <description>Pregnancy rate is defined as the cumulative percentage of pregnancies occuring within the time frame. The primary endpoint for this study is the pregnancy prevention rate after one year of reliance on the Adiana System for pregnancy prevention. The pregnancy rate was evaluated for all participants who underwent successful bilateral treatment and who had demonstrated tubal occlusion by hysterosalpingogram (HSG) at the end of the Waiting Period.</description>
          <population>645 participants had treatment attempted; Intent to Treat population. Of these 645, 570 were able to rely on the device and are used to evaluate the pregnancy prevention rate for the 1-year endpoint. During the 1-year follow-up period, there were 6 pregnancies, of which 3 were attributable to physician error, i.e., misinterpretation of HSG results.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="570"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>1-sided confidence interval. No statistical hypothesis testing was performed. Confidence interval represents a 1-sided confidence interval for the pregnancy prevention rate in the EASE Trial. 95% confidence interval derived using Kaplan Meier methods (log-log with PETO adjustment).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Pregnancy Prevention Rate</param_type>
            <param_value>98.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>97.9</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>2-sided confidence interval. No statistical hypothesis testing was performed. Confidence interval represents a 2-sided confidence interval for the pregnancy prevention rate in the EASE Trial. 95% confidence interval derived using Kaplan Meier methods (log-log with PETO adjustment).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Pregnancy Prevention Rate</param_type>
            <param_value>98.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>97.6</ci_lower_limit>
            <ci_upper_limit>99.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device Placement Rate</title>
        <description>Defined as successful bilateral tubal access followed by successful bilateral RF treatment and matrix placement.</description>
        <time_frame>After First Treatment Attempt</time_frame>
        <population>Device placement rate reported on a per participant basis for 645 intent to treat participants. Successful bilateral placement of the matrices was achieved in 604/645 participants after the first procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Adiana Permanent Contraception System</title>
            <description>Implantation of silicone matrix in fallopian tubes</description>
          </group>
        </group_list>
        <measure>
          <title>Device Placement Rate</title>
          <description>Defined as successful bilateral tubal access followed by successful bilateral RF treatment and matrix placement.</description>
          <population>Device placement rate reported on a per participant basis for 645 intent to treat participants. Successful bilateral placement of the matrices was achieved in 604/645 participants after the first procedure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="645"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device Placement Rate</title>
        <description>Defined as successful bilateral tubal access followed by successful bilateral RF treatment and matrix placement.</description>
        <time_frame>Including Second Treatment Attempt</time_frame>
        <population>Device placement rate reported on a per participant basis for 645 intent to treat participants. Successful bilateral placement of the matrices was achieved in 611/645 participants after 7 participants underwent a successful second attempt.</population>
        <group_list>
          <group group_id="O1">
            <title>Adiana Permanent Contraception System</title>
            <description>Implantation of silicone matrix in fallopian tubes</description>
          </group>
        </group_list>
        <measure>
          <title>Device Placement Rate</title>
          <description>Defined as successful bilateral tubal access followed by successful bilateral RF treatment and matrix placement.</description>
          <population>Device placement rate reported on a per participant basis for 645 intent to treat participants. Successful bilateral placement of the matrices was achieved in 611/645 participants after 7 participants underwent a successful second attempt.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="645"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Placement Procedure</title>
        <description>Determined by verbal questions up to 48 hours post placement. Endpoint reported represents minimum percentage of participants reporting somewhat satisfied, satisfied or very satisfied.</description>
        <time_frame>48 hours</time_frame>
        <population>Intent to treat population; no imputations for missing data. Minimum satisfaction reported as 605/625 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Adiana Permanent Contraception System</title>
            <description>Implantation of silicone matrix in fallopian tubes</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Placement Procedure</title>
          <description>Determined by verbal questions up to 48 hours post placement. Endpoint reported represents minimum percentage of participants reporting somewhat satisfied, satisfied or very satisfied.</description>
          <population>Intent to treat population; no imputations for missing data. Minimum satisfaction reported as 605/625 participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="625"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Device Wearing</title>
        <description>Determined by verbal questions during periodic follow-up contacts. Endpoint reported represents minimum percentage of subjects reporting somewhat satisfied, satisfied or very satisfied.</description>
        <time_frame>Waiting Period (1-Month, 2-Months, 3-Months)</time_frame>
        <population>Intent to treat population; no imputations for missing data. Minimum satisfaction reported at 2-Months as 587/613 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Adiana Permanent Contraception System</title>
            <description>Implantation of silicone matrix in fallopian tubes</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Device Wearing</title>
          <description>Determined by verbal questions during periodic follow-up contacts. Endpoint reported represents minimum percentage of subjects reporting somewhat satisfied, satisfied or very satisfied.</description>
          <population>Intent to treat population; no imputations for missing data. Minimum satisfaction reported at 2-Months as 587/613 participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="613"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Device Wearing</title>
        <description>Determined by verbal questions during periodic follow-up contacts. Endpoint reported represents minimum percentage of subjects reporting somewhat satisfied, satisfied or very satisfied.</description>
        <time_frame>Wearing Period (3-Months, 6-Months, 9-Months, 12-Months)</time_frame>
        <population>Per protocol population; no imputations for missing data. Minimum satisfaction reported at 12-Months as 528/531 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Adiana Permanent Contraception System</title>
            <description>Implantation of silicone matrix in fallopian tubes</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Device Wearing</title>
          <description>Determined by verbal questions during periodic follow-up contacts. Endpoint reported represents minimum percentage of subjects reporting somewhat satisfied, satisfied or very satisfied.</description>
          <population>Per protocol population; no imputations for missing data. Minimum satisfaction reported at 12-Months as 528/531 participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="531"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Comfort With Placement Procedure</title>
        <description>Determined by verbal questions two hours following procedure or at discharge from facility, whichever came first. Endpoint reported represents minimum percentage of participants reporting any discomfort or pain experienced during the procedure as the same as or less than they expected.</description>
        <time_frame>Post-Procedure</time_frame>
        <population>Intent to treat population; no imputations for missing data. Minimum comfort reported as 504/629 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Adiana Permanent Contraception System</title>
            <description>Implantation of silicone matrix in fallopian tubes</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Comfort With Placement Procedure</title>
          <description>Determined by verbal questions two hours following procedure or at discharge from facility, whichever came first. Endpoint reported represents minimum percentage of participants reporting any discomfort or pain experienced during the procedure as the same as or less than they expected.</description>
          <population>Intent to treat population; no imputations for missing data. Minimum comfort reported as 504/629 participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="629"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Comfort With Placement Procedure</title>
        <description>Determined by verbal questions up to 48 hours post placement. Endpoint reported represents minimum percentage of participants reporting any discomfort or pain experienced in first 48 hours following procedure as the same as they expected, less than they expected or no pain.</description>
        <time_frame>48 hours</time_frame>
        <population>Intent to treat population; no imputations for missing data. Minimum comfort reported as 578/632 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Adiana Permanent Contraception System</title>
            <description>Implantation of silicone matrix in fallopian tubes</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Comfort With Placement Procedure</title>
          <description>Determined by verbal questions up to 48 hours post placement. Endpoint reported represents minimum percentage of participants reporting any discomfort or pain experienced in first 48 hours following procedure as the same as they expected, less than they expected or no pain.</description>
          <population>Intent to treat population; no imputations for missing data. Minimum comfort reported as 578/632 participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="632"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Comfort With Device Wearing</title>
        <description>Determined by verbal questions during periodic follow-up contacts. Endpoint represents minimum percentage of subjects reporting good, very good or excellent comfort.</description>
        <time_frame>Waiting Period (1-Month, 2-Months, 3-Months)</time_frame>
        <population>Intent to treat population; no imputations for missing data. Minimum comfort reported at 1-Month as 604/608 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Adiana Permanent Contraception System</title>
            <description>Implantation of silicone matrix in fallopian tubes</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Comfort With Device Wearing</title>
          <description>Determined by verbal questions during periodic follow-up contacts. Endpoint represents minimum percentage of subjects reporting good, very good or excellent comfort.</description>
          <population>Intent to treat population; no imputations for missing data. Minimum comfort reported at 1-Month as 604/608 participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="608"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Comfort With Device Wearing</title>
        <description>Determined by verbal questions during periodic follow-up contacts. Endpoint represents minimum percentage of subjects reporting good, very good or excellent comfort.</description>
        <time_frame>Wearing Period (3-Months, 6-Months, 9-Months, 12-Months)</time_frame>
        <population>Per protocol population; no imputations for missing data. Minimum comfort reported at 12-Months as 530/532 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Adiana Permanent Contraception System</title>
            <description>Implantation of silicone matrix in fallopian tubes</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Comfort With Device Wearing</title>
          <description>Determined by verbal questions during periodic follow-up contacts. Endpoint represents minimum percentage of subjects reporting good, very good or excellent comfort.</description>
          <population>Per protocol population; no imputations for missing data. Minimum comfort reported at 12-Months as 530/532 participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="532"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>3 Year Pregnancy Rate</title>
        <description>Pregnancy rate is defined as the cumulative percentage of pregnancies occuring within the time frame. The pregnancy rate was evaluated for all participants who underwent successful bilateral treatment and who had demonstrated tubal occlusion by hysterosalpingogram (HSG) at the end of the Waiting Period who have been followed for up to 3 years.</description>
        <time_frame>3 years</time_frame>
        <population>Population includes all participants able to rely on Adiana (n=570). This analysis is cumulative and based on survival analysis methodology. Thus, participants only followed for 2 years, for example, would still be included in this cumulative analysis. In total, 481 participants were available with 3 years of follow-up at the time of analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Adiana Permanent Contraception System</title>
            <description>Implantation of silicone matrix in fallopian tubes</description>
          </group>
        </group_list>
        <measure>
          <title>3 Year Pregnancy Rate</title>
          <description>Pregnancy rate is defined as the cumulative percentage of pregnancies occuring within the time frame. The pregnancy rate was evaluated for all participants who underwent successful bilateral treatment and who had demonstrated tubal occlusion by hysterosalpingogram (HSG) at the end of the Waiting Period who have been followed for up to 3 years.</description>
          <population>Population includes all participants able to rely on Adiana (n=570). This analysis is cumulative and based on survival analysis methodology. Thus, participants only followed for 2 years, for example, would still be included in this cumulative analysis. In total, 481 participants were available with 3 years of follow-up at the time of analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="570"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>1-sided Confidence Interval.
No hypothesis testing was performed. Confidence interval represents a 1-sided confidence interval for the pregnancy prevention rate in the EASE trial. 95% confidence interval derived using Kaplan Meier methods (log-log with PETO adjustment).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Pregnancy Prevention Rate</param_type>
            <param_value>98.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>97.2</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>2-sided Confidence Interval
No hypothesis testing was performed. Confidence interval represents a 2-sided confidence interval for the pregnancy prevention rate in the EASE trial. 95% confidence interval derived using Kaplan Meier methods (log-log with PETO adjustment).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Pregnancy Prevention Rate</param_type>
            <param_value>98.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>96.9</ci_lower_limit>
            <ci_upper_limit>99.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Post-procedure, 48-Hours, 1-Week, 1-Month, 2-Months, 3-Months (Waiting Period), 3-Months (Wearing Period), participant diary through the 3-Month Wearing Period, 6-Months, 9-Months, 12-Months, 18-Months, 24-Months, 36-Months.</time_frame>
      <desc>Questions were asked through the 12-Month visit to assess subjects' presence or absence of post-operative discomfort. Subjects completed a participant diary detailing menstrual and sexual activity, and any symptoms, through the 3-Month Wearing Period. Follow-up visits included an assessment of subjects' potential adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Adiana Permanent Contraception System</title>
          <description>Implantation of silicone matrix in fallopian tubes</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (7.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Keratoconjunctivitis sicca</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Nerve injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Pain trauma activated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of spinal cord</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Thyroid gland cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Monoplegia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Gastric bypass</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Hernia hiatus repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Mastectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (7.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="642" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="76" subjects_affected="55" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="82" subjects_affected="51" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="40" subjects_affected="35" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="270" subjects_affected="199" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="89" subjects_affected="74" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="118" subjects_affected="44" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="90" subjects_affected="78" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="115" subjects_affected="90" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="73" subjects_affected="59" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="44" subjects_affected="38" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="78" subjects_affected="65" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Vaginal mycosis</sub_title>
                <counts group_id="E1" events="58" subjects_affected="43" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="36" subjects_affected="34" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Post procedural pain</sub_title>
                <counts group_id="E1" events="118" subjects_affected="91" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="178" subjects_affected="116" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1139" subjects_affected="385" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Muscle cramp</sub_title>
                <counts group_id="E1" events="895" subjects_affected="485" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="76" subjects_affected="47" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="61" subjects_affected="40" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2006" subjects_affected="428" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="241" subjects_affected="70" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" events="83" subjects_affected="42" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="62" subjects_affected="59" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="49" subjects_affected="36" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="83" subjects_affected="75" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Amenorrhoea</sub_title>
                <counts group_id="E1" events="51" subjects_affected="36" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="2860" subjects_affected="520" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Dyspareunia</sub_title>
                <counts group_id="E1" events="186" subjects_affected="101" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="269" subjects_affected="146" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" events="66" subjects_affected="52" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="1149" subjects_affected="573" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Muscle cramp</sub_title>
                <counts group_id="E1" events="76" subjects_affected="72" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="924" subjects_affected="346" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Polymenorrhoea</sub_title>
                <counts group_id="E1" events="42" subjects_affected="33" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="208" subjects_affected="188" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" events="738" subjects_affected="284" subjects_at_risk="645"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="515" subjects_affected="255" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="44" subjects_affected="38" subjects_at_risk="645"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All publications must be submitted for review and approval at least (30) days before the date on which it is to be submitted.
No publication of data wil be permitted prior to the submission and publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>At the time of analysis, 481 completed 3 years. Due to the cumulative nature of the analysis, subjects may be lost to follow-up at one time and return to follow-up at a subsequent point. All subjects who have not withdrawn consent will be followed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Edward Evantash, MD, Medical Director, Vice President Medical Affairs</name_or_title>
      <organization>Hologic, Inc.</organization>
      <phone>508-263-8475</phone>
      <email>edward.evantash@hologic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

